YGEN — Yourgene Health Share Price
Last trade - 00:00- £16.45m
- £31.98m
- £37.56m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.61 | ||
| Price to Tang. Book | 3.78 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.53 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.73% | ||
| Return on Equity | -27.06% | ||
| Operating Margin | -27.09% | ||
Financial Summary
| Year End 31st Mar | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 6.15 | 8.88 | 16.61 | 18.29 | 37.56 | 18.7 | 19.65 | 64.92% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Yourgene Health PLC is an integrated molecular diagnostics company. The Company primarily develops, manufactures, and commercializes molecular diagnostic solutions for reproductive health, precision medicine and infectious diseases. Its segments include Genomic Technologies, which provides in vitro diagnostic products, software and instrumentation, and Genomic Services, which provides services to clinicians, third party clinical service providers and contract research organizations. Its flagship products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and an extension into the precision medicine space with DPYD genotyping. It has a range of deoxyribonucleic (DNA) sample preparation platforms, powered by Ranger Technology, the Yourgene LightBench and Yourgene QS250, ideal for cell-free DNA applications in non-invasive prenatal tests and oncology, including liquid biopsy.
Directors
- Adam Reynolds NEC (59)
- Lyn Rees CEO (47)
- Stephen Little NVC
- Barry Hextall CFO (53)
- Hayden Jeffreys COO (45)
- Joanne Mason CSO
- Scott Sargent VPR
- Bill Chang EDR
- Jonathan Seaton NED (51)
- Mary Tavener NED (60)
- John Brown NID
- Last Annual
- March 31st, 2022
- Last Interim
- September 30th, 2022
- Incorporated
- April 13th, 2000
- Public Since
- May 21st, 2002
- No. of Employees
- 243
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 3,193,466,515
- Address
- Citylabs 1.0, Nelson Street, MANCHESTER, M15 6SH
- Web
- https://www.yourgene-health.com/
- Phone
- +44 1616698122
- Auditors
- Saffery Champness LLP
Latest News for YGEN
Upcoming Events for YGEN
Half Year 2024 Yourgene Health PLC Earnings Release
Yourgene Health PLC Annual Shareholders Meeting
Similar to YGEN
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 07:26 UTC, shares in Yourgene Health are trading at 0.50p. This share price information is delayed by 15 minutes.
Shares in Yourgene Health last closed at 0.50p and the price had moved by -93.61% over the past 365 days. In terms of relative price strength the Yourgene Health share price has underperformed the FTSE All Share Index by -93.82% over the past year.
The overall consensus recommendation for Yourgene Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Yourgene Health does not currently pay a dividend.
Yourgene Health does not currently pay a dividend.
Yourgene Health does not currently pay a dividend.
To buy shares in Yourgene Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 0.50p, shares in Yourgene Health had a market capitalisation of £15.81m.
Here are the trading details for Yourgene Health:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: YGEN
Based on an overall assessment of its quality, value and momentum Yourgene Health is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Yourgene Health is 1.10p. That is 122.22% above the last closing price of 0.50p.
Analysts covering Yourgene Health currently have a consensus Earnings Per Share (EPS) forecast of -£0.01 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Yourgene Health. Over the past six months, its share price has outperformed the FTSE All Share Index by +26.02%.
As of the last closing price of 0.50p, shares in Yourgene Health were trading -50.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Yourgene Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 0.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Yourgene Health's management team is headed by:
- Adam Reynolds - NEC
- Lyn Rees - CEO
- Stephen Little - NVC
- Barry Hextall - CFO
- Hayden Jeffreys - COO
- Joanne Mason - CSO
- Scott Sargent - VPR
- Bill Chang - EDR
- Jonathan Seaton - NED
- Mary Tavener - NED
- John Brown - NID